Captrust Financial Advisors Lineage Cell Therapeutics, Inc. Transaction History

Captrust Financial Advisors

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$1.21 - $2.48 $820 - $1,681	-678 Closed	0 $0
Q3 2021 Nov 16, 2021	SELL	$2.26 - $2.86 $131 - $165	-58 Reduced 7.88%	678 $2,000
Q2 2021 Aug 16, 2021	BUY	$2.17 - $3.0 $1,471 - $2,034	678 Added 1168.97%	736 $2,000
Q2 2020 Aug 14, 2020	BUY	$0.71 - $1.18 $41 - $68	58 New	58 $0

122

94.2M

63.8K

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $149M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.